Cargando…
Immunohistochemistry with anti-MAL antibody and RNAscope with MAL probes are complementary techniques for diagnosis of primary mediastinal large B-cell lymphoma
AIMS: Primary mediastinal large B-cell lymphoma (PMBL) diagnosis can be challenging on needle biopsies. Robust techniques are needed to ensure diagnosis of this lymphoma which is highly sensitive to recently developed therapy protocols. METHODS: In this study, we sought to determine precise PMBL phe...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8142454/ https://www.ncbi.nlm.nih.gov/pubmed/32839159 http://dx.doi.org/10.1136/jclinpath-2020-206747 |
_version_ | 1783696555350425600 |
---|---|
author | Jacquier, Anthony Syrykh, Charlotte Bedgedjian, Isabelle Monnien, Franck Laurent, Camille Valmary-Degano, Séverine Brousset, Pierre |
author_facet | Jacquier, Anthony Syrykh, Charlotte Bedgedjian, Isabelle Monnien, Franck Laurent, Camille Valmary-Degano, Séverine Brousset, Pierre |
author_sort | Jacquier, Anthony |
collection | PubMed |
description | AIMS: Primary mediastinal large B-cell lymphoma (PMBL) diagnosis can be challenging on needle biopsies. Robust techniques are needed to ensure diagnosis of this lymphoma which is highly sensitive to recently developed therapy protocols. METHODS: In this study, we sought to determine precise PMBL phenotype, compared with diffuse large B-cell lymphoma not otherwise specified, by combining immunohistochemistry with anti-MAL antibody and RNA in situ hybridisation (RNAscope) with specific MAL probes. RESULTS: The overall MAL positivity level reached 93% (14/15) of cases of PMBL. Among the 15 cases enrolled in the study, 11 were undoubtedly positive for MAL immunostaining whereas 13 were positive by RNA in situ hybridisation. Interestingly, one case that was negative by in situ hybridisation turned out to be positive by immunohistochemistry. CONCLUSIONS: Taken together, our results demonstrate that in situ detection of both MAL transcripts and protein are complementary and increase the sensitivity and specificity of PMBL diagnosis. |
format | Online Article Text |
id | pubmed-8142454 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-81424542021-06-07 Immunohistochemistry with anti-MAL antibody and RNAscope with MAL probes are complementary techniques for diagnosis of primary mediastinal large B-cell lymphoma Jacquier, Anthony Syrykh, Charlotte Bedgedjian, Isabelle Monnien, Franck Laurent, Camille Valmary-Degano, Séverine Brousset, Pierre J Clin Pathol Short Report AIMS: Primary mediastinal large B-cell lymphoma (PMBL) diagnosis can be challenging on needle biopsies. Robust techniques are needed to ensure diagnosis of this lymphoma which is highly sensitive to recently developed therapy protocols. METHODS: In this study, we sought to determine precise PMBL phenotype, compared with diffuse large B-cell lymphoma not otherwise specified, by combining immunohistochemistry with anti-MAL antibody and RNA in situ hybridisation (RNAscope) with specific MAL probes. RESULTS: The overall MAL positivity level reached 93% (14/15) of cases of PMBL. Among the 15 cases enrolled in the study, 11 were undoubtedly positive for MAL immunostaining whereas 13 were positive by RNA in situ hybridisation. Interestingly, one case that was negative by in situ hybridisation turned out to be positive by immunohistochemistry. CONCLUSIONS: Taken together, our results demonstrate that in situ detection of both MAL transcripts and protein are complementary and increase the sensitivity and specificity of PMBL diagnosis. BMJ Publishing Group 2021-06 2020-08-24 /pmc/articles/PMC8142454/ /pubmed/32839159 http://dx.doi.org/10.1136/jclinpath-2020-206747 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Short Report Jacquier, Anthony Syrykh, Charlotte Bedgedjian, Isabelle Monnien, Franck Laurent, Camille Valmary-Degano, Séverine Brousset, Pierre Immunohistochemistry with anti-MAL antibody and RNAscope with MAL probes are complementary techniques for diagnosis of primary mediastinal large B-cell lymphoma |
title | Immunohistochemistry with anti-MAL antibody and RNAscope with MAL probes are complementary techniques for diagnosis of primary mediastinal large B-cell lymphoma |
title_full | Immunohistochemistry with anti-MAL antibody and RNAscope with MAL probes are complementary techniques for diagnosis of primary mediastinal large B-cell lymphoma |
title_fullStr | Immunohistochemistry with anti-MAL antibody and RNAscope with MAL probes are complementary techniques for diagnosis of primary mediastinal large B-cell lymphoma |
title_full_unstemmed | Immunohistochemistry with anti-MAL antibody and RNAscope with MAL probes are complementary techniques for diagnosis of primary mediastinal large B-cell lymphoma |
title_short | Immunohistochemistry with anti-MAL antibody and RNAscope with MAL probes are complementary techniques for diagnosis of primary mediastinal large B-cell lymphoma |
title_sort | immunohistochemistry with anti-mal antibody and rnascope with mal probes are complementary techniques for diagnosis of primary mediastinal large b-cell lymphoma |
topic | Short Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8142454/ https://www.ncbi.nlm.nih.gov/pubmed/32839159 http://dx.doi.org/10.1136/jclinpath-2020-206747 |
work_keys_str_mv | AT jacquieranthony immunohistochemistrywithantimalantibodyandrnascopewithmalprobesarecomplementarytechniquesfordiagnosisofprimarymediastinallargebcelllymphoma AT syrykhcharlotte immunohistochemistrywithantimalantibodyandrnascopewithmalprobesarecomplementarytechniquesfordiagnosisofprimarymediastinallargebcelllymphoma AT bedgedjianisabelle immunohistochemistrywithantimalantibodyandrnascopewithmalprobesarecomplementarytechniquesfordiagnosisofprimarymediastinallargebcelllymphoma AT monnienfranck immunohistochemistrywithantimalantibodyandrnascopewithmalprobesarecomplementarytechniquesfordiagnosisofprimarymediastinallargebcelllymphoma AT laurentcamille immunohistochemistrywithantimalantibodyandrnascopewithmalprobesarecomplementarytechniquesfordiagnosisofprimarymediastinallargebcelllymphoma AT valmarydeganoseverine immunohistochemistrywithantimalantibodyandrnascopewithmalprobesarecomplementarytechniquesfordiagnosisofprimarymediastinallargebcelllymphoma AT broussetpierre immunohistochemistrywithantimalantibodyandrnascopewithmalprobesarecomplementarytechniquesfordiagnosisofprimarymediastinallargebcelllymphoma |